An evergreen fund makes equity investments in early- to late-stage private businesses. Typical allocations range from USD 1.5 million to north of USD 10 million. The firm is most interested in companies addressing North Asia, USA, Europe, and LATAM markets.
The firm will invest in therapeutics, medical devices, diagnostics, and digital health products. In therapeutics, the firm is currently most interested in cell and gene therapy, nucleic acid drugs, and all novel drug delivery products. The firm prefers to invest from early clinical stage (Phase I) and beyond. In medical devices, the firm is opportunistic and is open to all types of technologies. In diagnostics, the firm is primarily interested in IVD and diagnostics tools. The firm prefers to invest in products that have entered clinical testing, and is open to investing in both 510k and PMA devices. Lastly, in digital health, the firm is open to all types of technologies including those that leverage AI. In terms of indications, the firm is most interested in chronic disease therapy / care, neuron disorders, and oncology.
The firm is looking for competent, experienced, and reliable management teams when considering investment. The fund typically requires a board seat in the companies it invests in.
If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.
Next Phase Newsletter 
Leave a comment